Myriad Genetics launches "Know More Sooner" website for educational resources on reproductive and prenatal genetic testing.
Quiver AI Summary
Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to educate prospective parents on the benefits of prenatal genetic screening, dispelling common myths and offering guidance on screening options and potential next steps for high-risk results. It features patient stories to highlight how these screenings can assist in managing pregnancies. Despite the American College of Obstetricians and Gynecologists recommending such screenings for all pregnant patients, many women reported not being offered noninvasive prenatal testing. The website addresses the knowledge gap about genetic testing's benefits and includes details on Myriad's offerings, such as the SneakPeek® Gender Test, Foresight® Carrier Screen, and Prequel® Prenatal Screen, which help parents understand their baby's genetic risks early in the pregnancy.
Potential Positives
- Myriad Genetics has launched an educational website, "Know More Sooner," which enhances public understanding of reproductive and prenatal genetic testing, potentially increasing demand for their services.
- The initiative addresses a significant gap revealed by a survey, highlighting that many women desire access to prenatal screening once they understand its importance, indicating a strong market opportunity for the company.
- The release underscores the company's commitment to patient education and support, positioning Myriad as a leader in genetic testing and prenatal care, which may strengthen brand trust and loyalty.
- Myriad offers innovative genetic tests with high accuracy, reinforcing their technological expertise and attracting more clients seeking reliable prenatal genetic testing solutions.
Potential Negatives
- Despite the launch of the "Know More Sooner" website, a significant portion (40%) of survey respondents reported not being offered noninvasive prenatal testing, indicating potential shortcomings in Myriad Genetics' outreach or education efforts in the prenatal screening market.
- The necessity for the educational website suggests that there may be a widespread lack of awareness and understanding regarding the benefits of prenatal genetic testing among patients, which could reflect poorly on the company's communication and marketing strategies.
- Forward-looking statements in the release imply optimism about prenatal screening benefits, but the acknowledgment of "known and unknown risks and uncertainties" might raise concerns among investors about the company's future performance and execution of its strategic initiatives.
FAQ
What is the "Know More Sooner" website?
The "Know More Sooner" website offers educational resources about prenatal genetic testing, benefits, and myths surrounding it.
How can prenatal genetic testing benefit expectant parents?
Prenatal genetic testing provides insights early in pregnancy, helping parents prepare and make informed decisions about their baby's health.
What types of genetic tests does Myriad Genetics offer?
Myriad Genetics offers the SneakPeek® Gender Test, Foresight® Carrier Screen, and Prequel® Prenatal Screen to expectant parents.
Why was the "Know More Sooner" website created?
The website was created to increase understanding of prenatal genetic testing and address the lack of awareness among expectant parents.
What do surveys reveal about women's attitudes toward prenatal screening?
Surveys show most women want prenatal screening if they understand how it can reduce genetic risks during pregnancy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MYGN Insider Trading Activity
$MYGN insiders have traded $MYGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $MYGN stock by insiders over the last 6 months:
- COLLEEN F REITAN sold 46,012 shares for an estimated $1,285,851
- PAUL J DIAZ (President and CEO) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $744,750.
- MARGARET ANCONA (SVP, Chief of Staff) sold 11,538 shares for an estimated $320,987
- HEINRICH DREISMANN sold 10,000 shares for an estimated $270,520
- RASHMI KUMAR sold 7,500 shares for an estimated $210,075
- DALE MUZZEY (Chief Scientific Officer) sold 2,100 shares for an estimated $54,961
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MYGN Hedge Fund Activity
We have seen 125 institutional investors add shares of $MYGN stock to their portfolio, and 102 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 2,486,902 shares (-66.3%) from their portfolio in Q3 2024, for an estimated $68,116,245
- CITADEL ADVISORS LLC removed 1,695,989 shares (-96.1%) from their portfolio in Q3 2024, for an estimated $46,453,138
- CAMBER CAPITAL MANAGEMENT LP removed 1,550,000 shares (-28.2%) from their portfolio in Q3 2024, for an estimated $42,454,500
- WELLINGTON MANAGEMENT GROUP LLP removed 1,545,842 shares (-18.7%) from their portfolio in Q3 2024, for an estimated $42,340,612
- LOOMIS SAYLES & CO L P added 1,326,497 shares (+153.7%) to their portfolio in Q3 2024, for an estimated $36,332,752
- MILLENNIUM MANAGEMENT LLC added 777,499 shares (+17.7%) to their portfolio in Q3 2024, for an estimated $21,295,697
- MORGAN STANLEY removed 491,650 shares (-35.8%) from their portfolio in Q3 2024, for an estimated $13,466,293
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information about reproductive and prenatal genetic testing.
The “ Know More Sooner ” website provides the benefits and dispels the common myths of prenatal genetic testing, as well as where to get screened and what actions can be taken in the instance of a high-risk result. The site features real-life patient stories to illustrate how prenatal screening can help parents-to-be manage their pregnancies.
“Many patients don’t initially understand the importance of prenatal genetic screening, but with Myriad’s prenatal screens, couples can discover helpful insights earlier in the pregnancy,” said Dallas Reed, MD, FACMG, FACOG, obstetrician-gynecologist and medical geneticist who serves as the Principal Medical Advisor of Women’s Health for Myriad Genetics. “Having this information allows patients to meet with specialists sooner, choose a birthing location appropriate for their situation, and/or talk with others who have had similar experiences.”
The Know More Sooner website was created in response to a survey revealing that the majority of women want prenatal screening once they understand how genetic testing can provide insights into their pregnancy’s genetic risks, helping them learn more and to prepare for their baby. However, four in 10 survey respondents reported that they had not been offered any form of noninvasive prenatal testing (NIPT), also known as prenatal cell-free DNA (cfDNA) screening. 1
The American College of Obstetricians and Gynecologists (ACOG) recommends that carrier and cfDNA screening be offered to all pregnant patients regardless of ancestry, maternal age, or risk of chromosomal abnormality. 2,3
“The lack of understanding of the benefits of genetic testing is why we created the Know More Sooner website. Offering resources, answering questions, and sharing basics about genetic testing are essential steps in helping women better understand pregnancy and make informed decisions,” said Melissa Gonzales, President, Myriad Women’s Health. “Most families find genetic screening reassuring. If a possible concern is identified, screening gives you time to pursue diagnostic testing and learn more about your baby’s needs from the start.”
Myriad offers three genetic tests to those who are pregnant or are considering becoming pregnant:
- The SneakPeek ® Gender Test predicts fetal sex as early as six weeks into pregnancy with greater than 99% accuracy. 4
- The Foresight ® Carrier Screen identifies those who have a chance of passing down serious inherited conditions.
-
The
Prequel
®
Prenatal Screen
identifies whether a pregnancy is at an increased risk for a wide variety of chromosomal conditions as early as eight weeks.
References
1. Large scale Pollfish survey of 1,000 US-based population who self-identified as 'pregnant' or 'recently pregnant.' Survey was conducted by the S50 Agency on behalf of Myriad Genetics, December 2023.
2. ACOG Practice Bulletin #226: Screening for Fetal Chromosomal Abnormalities. Obstet Gynecol. 2020;136.
3. Committee Opinion 690. ACOG. Obstet Gynecol. 2017;129:e35-40. 3. Arroyo-Johnson C,
Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North 463 Am. 2016 Dec;45(4):571–9.
4. In a large-scale published study run in 2020, SneakPeek accurately determined fetal sex in 99.9% of 1,029 pregnant women between 7-37 weeks gestational age. In a 2021 laboratory test, SneakPeek accurately determined fetal sex in 99.02% of 102 pregnant women using the Snap device at 8-15 weeks gestational age. In a separate published study run in 2021, fetal sex was accurately determined in 100% of 134 pregnant women at 7 weeks gestational age. In a 2022 scientific study, SneakPeek accurately determined fetal sex for 100% of 103 women at 6 weeks gestational age.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit
www.myriad.com
.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company’s prenatal screens can help couples discover valuable insights earlier in pregnancy and having this information allows patients to meet with specialists sooner, choose a birthing location appropriate to their situation, and/or talk with others who have had similar experience, and statements relating to how most families find genetic screening reassuring. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
[email protected]
Media Contact
Glenn Farrell
(385) 318-3718
[email protected]